Close Menu

Karius

The firm argues that its tests allows hospitals to expedite patient treatment, while curbing the costs of one-off tests and medication, and minimizing the length of a patient's stay. 

The firm will use the funding to expand access to its microbial cell-free DNA technology to help doctors diagnose infectious disease.

St. Jude Children's Research Hospital researchers evaluated a microbial cell-free DNA sequencing test from infectious disease diagnostics firm Karius.

In Nature this week: genomic factors that influence glioblastoma response to anti-PD-1 therapy, sequencing test for infectious disease, and more.

While the study showed initial promise, further work will be necessary to clarify its performance for various clinical indications.

Karius said it will use the money to continue commercialization of its diagnostic technologies and to fund clinical studies, among other things.

The test can detect over 1,000 pathogens — including bacteria, DNA viruses, fungi, mold, and protozoa — from microbial cell-free DNA in a single blood draw.

The Stanford spinout has launched an infectious disease test that sequences cell-free pathogen DNA to diagnose sepsis in immunocompromised patients.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.